Lakefront Biotherapeutics American Depositary Shares
LKFT
83 hedge funds and large institutions have $783M invested in Lakefront Biotherapeutics American Depositary Shares in 2025 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 22 increasing their positions, 30 reducing their positions, and 15 closing their positions.
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
2% more funds holding
Funds holding: 81 → 83 (+2)
0.17% more ownership
Funds ownership: 47.16% → 47.33% (+0.17%)
9% less capital invested
Capital invested by funds: $857M → $783M (-$73.7M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
26% less call options, than puts
Call options by funds: $6.42M | Put options by funds: $8.68M
27% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$45.5M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$7.33M |
| 3 |
Jane Street
New York
|
+$2.52M |
| 4 |
JGC
J. Goldman & Co
New York
|
+$2.13M |
| 5 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$1.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$38.8M |
| 2 |
Primecap Management
Pasadena,
California
|
-$12.2M |
| 3 |
BlackRock
New York
|
-$4.31M |
| 4 |
Morgan Stanley
New York
|
-$3M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$2.91M |
LKFT Hedge Fund Activity: Q1 2025 in Review
83 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q1 2025, worth a combined $783M — down 8.6% from $857M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new LKFT positions and 15 closed out — a net gain of 2 holders — while 22 added to existing stakes and 30 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $45.5M. The largest seller was Deerfield Management, exiting entirely with an estimated $38.8M sold.
- 83 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q1 2025, up from 81 in Q4 2024.
- Funds reported $783M of Lakefront Biotherapeutics American Depositary Shares stock for Q1 2025, down 8.6% quarter-over-quarter.
- 17 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q1 2025 and 15 closed out, a net change of +2 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q1 2025 was Tang Capital Management, an estimated $45.5M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q1 2025 was Deerfield Management, an estimated $38.8M sold.
Based on aggregated 13F filings for Q1 2025.